Taro Pharmaceutical Industries Ltd, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is BETAMETHASONE DIPROPIONATE USP, MICRONIZED, with a corresponding US DMF Number 14651.
Remarkably, this DMF maintains an Active status since its submission on December 30, 1999, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of April 24, 2017, and payment made on April 06, 2017, indicating their dedication to facilitating drug approvals, Categorized as Type II